Statins have been bedrock in lipid lowering therapy for decades but have come with adverse effects that are subject to exaggeration and discontinuation. Many have asked, is there a new class of drugs that will someday replace statins? This post signifies a breakthrough.

TheCORALreef Lipids trialwas a large, phase 3, multinational, randomized, double‑blind, placebo‑controlled study evaluating the efficacy and safety ofenlicitide decanoate (Merck), a first‑in‑classoral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, for lowering low‑density lipoprotein cholesterol (LDL‑C). The trial addressed an important unmet need: despite strong evidence that intensive LDL‑C lowering reduces cardiovascular risk, many high‑risk patients fail to achieve guideline‑recommended LDL‑C targets, in part because currently available PCSK9 inhibitors require injection every two weeks and are commonly rejected for insurance coverage. An effective oral PCSK9 inhibitor could substantially improve uptake and long‑term adherence.

CORALreef Lipids enrolled2,909 adultsacross168 sites in 14 countries. Participants either had a prior major atherosclerotic cardiovascular disease (ASCVD) event or were at intermediate to high risk for a first ASCVD event. Entry criteria requiredLDL‑C ≥55 mg/dLin those with established ASCVD or≥70 mg/dLin those at elevated primary‑prevention risk.

Importantly, participants were required to be onstable background lipid‑lowering therapybefore randomization. At baseline,96.6% of participants were receiving a statin, and95.4% were on moderate‑ or high‑intensity statin therapy, reflecting contemporary guideline‑directed care. Approximately26% were also receiving ezetimibe or hybutimibe, highlighting that this was a population with residual hypercholesterolemia despite optimized standard therapy. Only a small minority were statin‑intolerant.

Participants were randomized in a2:1 ratioto receiveenlicitide 20 mg orally once dailyor placebo for52 weeks. Randomization was stratified by renal function, baseline statin use, and geographic region. Theprimary endpointwas the mean percent change in LDL‑C from baseline toweek 24, with key secondary endpoints including LDL‑C change at week 52 and changes in non‑HDL cholesterol, apolipoprotein B (apoB), and lipoprotein(a).

Enlicitide producedrobust and clinically meaningful reductions in LDL‑Con top of background statin therapy. At baseline, mean LDL‑C was approximately96 mg/dL. By week 24, LDL‑C fell to~39 mg/dLin the enlicitide group, compared with~99 mg/dLin the placebo group.

Themean percent reduction in LDL‑C at week 24 was −57.1%with enlicitide versus a3.0% increasewith placebo, yielding anadjusted between‑group difference of −55.8 percentage points (P < 0.001). LDL‑C lowering remained durable through 52 weeks, with a−47.6 percentage‑point placebo‑adjusted reductionat one year. A post‑hoc analysis using revised handling of beta‑quantification values showed even larger reductions, approaching−60 percentage points.

These effects arecomparable to injectable monoclonal antibody PCSK9 inhibitorsand exceed those typically observed with other oral nonstatin therapies such as ezetimibe or bempedoic acid. Enlicitide also significantly reducednon‑HDL cholesterol (−53%),apoB (−50%), andlipoprotein(a) (−28%), supporting a broad favorable impact on atherogenic lipoproteins.

Clinically relevant LDL‑C targets were achieved by a large proportion of patients. At week 24,70% of enlicitide‑treated participants achieved LDL‑C <70 mg/dL with ≥50% reduction, and67.5% achieved LDL‑C <55 mg/dL with ≥50% reduction, compared with approximately1–2%in the placebo group. These results are notable given that nearly all participants were already receiving statins, often at high intensity.

Enlicitide demonstrated afavorable safety profileover 52 weeks of treatment. Theoverall incidence of adverse events,serious adverse events,treatment discontinuation due to adverse events, anddeathdidnot differ meaningfully between enlicitide and placebo.

Source: Global Research